Last Updated on December 17, 2022 by The Health Master
New Delhi: Neuropathic pain (NP), which is defined as pain caused by a lesion or disease of the somatosensory nervous system by the International Association for the Study of Pain, has a prevalence of 6%–19% worldwide.
Meanwhile, in epidemiological studies from India from various regions, the overall prevalence of Peripheral Neuropathy varies up to 2400 per 10,000 populations in various community studies.
Also, as per the Neuropathy Symptom Score (NSS) and Neuropathy Disability Score (NDS) criteria, the prevalence of diabetic peripheral neuropathy (DPN) is around 29.2%.
Though it has become a common disorder, it is a diagnostic and therapeutic challenge for physicians and neurologists across the country.
It can be a challenging disorder to manage because of the heterogeneity of its aetiologies, symptoms, and underlying mechanisms.
Moreover, current treatment options for neuropathic pain are mainly focused on neuronal system suppression rather than treating the inherent cause of NP.
Furthermore, most of the drugs used for the treatment of NP tend to cause drowsiness, dizziness, blurred vision, somnolence, peripheral edema, psychomotor slowing, and paraesthesia.
These side effects decrease the quality of Life of the patient and also reduce active working life.
Given the increasing prevalence of the disorder, an innovative treatment approach was unquestionably required.
The research over the last few years suggests that there are more important targets for pain, which are being missed.
Most notable of these research works were done by an Italian Nobel laureate Rita Levi-Montalcini honored for her work in neurobiology to establish the role of inflammatory cells in neuropathic pain management.
She helped identify an endogenous cannabinoid system in both the brain and the immune system along with a natural brain lipid amide which was subsequently shown to regulate the NP mechanisms in the human body.
Despite these findings, the problem remained of the external application of the said endogenous fatty acid amide.
The endogenous amide which is now known as Palmitoylethanolamide being fat soluble had a relatively very low level of absorption.
Further, a group of enzymes by the name of Fatty Acid Amide Hydrolase (FAAH Enzymes) present in the human system further worked to counter any exogenous supplementation of the said amide making the application futile.
Ahmedabad-based La Renon Healthcare developed a proprietary technology by the name of MPFAITECH and was able to address the aforesaid concerns with the endogenous amide and exogenous supplementation, becoming the first company in the world to show the synergistic action of the amide with a natural FAAH inhibitor.
They launched their product under the name PALMIGES in 2018 and at present have more than 40,000 Indian patients on the innovative product.
Given its success stories in India as a pain management therapy, La Renon planned to spread this novelty worldwide.
At the onset, the team applied for its patent globally including the likes of North and South American majors along with Europe, SEA, and the rest of the world. As they had expected, they began getting positive responses beginning with Canada.
The Canadian Patent Office recently granted a patent to Palmiges. The excitement got magnified as Europe also allowed a patent catering to 40 countries of the region.
The team is expecting more developments to follow in the coming months but for now, Indian innovation Palmiges has begun garnering a lot of international attention.
This suggests the potential of the composition and the impact it can create.
La Renon Healthcare, already established in many other therapeutic domains of chronic disease management, focused their resources and their inventive approach on their CNS division and developed this unique formula, Palmiges.
The aim was to find a better than existing solution for neuropathic pain management which is not only an agonizing experience for the patient but also a long-lasting and deep-rooted ailment.
Unlike many drugs that were generally administered for neuropathic pain, Palmiges was developed in a way that it was free of side effects and any Drug-Drug Interaction (DDI) and hence has garnered so much trust in the Indian market and is now set to venture into the regulated international markets with these simultaneous patent nods.
Chairman, Pankaj Singh said, “We believe that we in India have immense potential to offer innovation in so many sectors, including healthcare.
This is just one of the attempts to take the impact of the ‘Make in India’ movement to different books of the world and it is our constant endeavor to make it more sustainable by pooling our products with novelty and a differentiating approach.”
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
